Fishbain J, Peleg AY
Division of Infectious Diseases, St John Hospital and Medical Center, Detroit, Michigan 48236, USA. Joel.Fishbain@stjohn.org
SourceClin Infect Dis 2010 Jul 1; 51(1)
Acinetobacter baumannii remains an important and difficult-to-treat pathogen whose resistance patterns result in significant challenges for the clinician. Despite the prevalence and interest in A. baumannii infections, there is relatively limited well-controlled scientific data to help the clinician select optimal empirical and subsequent targeted therapy for a variety of infections. We will review the currently available antimicrobial agents and discuss the clinical data supporting the use of the various agents.
MeshAcinetobacter InfectionsAcinetobacter baumanniiAnti-Infective AgentsDrug Resistance, BacterialDrug Therapy, CombinationHumans
Journal Article Review